Kyntra Bio Emerges as Oncology and Rare Disease Focused Biotech

FibroGen has rebranded as Kyntra Bio to focus on oncology and rare disease assets. The company's common stock will trade under the new Nasdaq symbol "KYNB" starting January 8, 2026. Kyntra Bio has a sharpened direction, focusing on mid- and late-stage assets, including FG-3246, FG-3180, and roxadustat. Topline results from the FG-3246 Phase 1b/2 study and interim results from the Phase 2 monotherapy trial are expected in Q1 and H2 2026, respectively. Roxadustat received Orphan Drug Designation from the FDA for the treatment of myelodysplastic syndromes.